QT IMAGING HOLDINGS, INC. current report, 08 December 2022

Full document

Business Context and Reporting Period

GigCapital5, Inc. filed this Form 8-K in connection with its execution of a Business Combination Agreement dated December 8, 2022, with QT Imaging, Inc. and QTI Merger Sub, Inc. The filing was signed and the transaction was announced on December 12, 2022. GigCapital5 is a special purpose acquisition company; the proposed transaction would create QT Imaging Holdings, Inc. (“QTI Holdings”).

QT Imaging develops breast-imaging systems, including QTscan. The filing primarily describes the proposed business combination and related agreements; it does not provide a clear set of historical revenue, profit, cash flow, margin, or liquidity figures for QT Imaging.

Transaction Terms and Key Financial Metrics

  • QTI Merger Sub will merge with QT Imaging, with QT Imaging surviving as a wholly owned subsidiary of GigCapital5.
  • The post-closing company is expected to be renamed QT Imaging Holdings, Inc.
  • The stated Aggregate Closing Merger Consideration Value is based on $151.0 million, plus in-the-money warrant exercise proceeds, QT Imaging cash, and paid transaction expenses, less QT Imaging debt.
  • QT Imaging debt after conversion of applicable convertible notes may not exceed $4.0 million at closing.
  • Transaction expenses exceeding $4.0 million may reduce the shares issued to QT Imaging equity holders.
  • GigCapital5 may raise up to $26.0 million in gross proceeds through a potential PIPE investment, subject to mutually agreeable terms.
  • QT Imaging equity holders will have a contingent right to receive up to 9.0 million earnout shares, subject to specified regulatory, revenue, product-placement, clinical, and stock-price milestones.
  • A QTI Holdings equity incentive plan is expected to reserve shares equal to 11% of fully diluted post-closing shares, with an annual evergreen increase equal to 5% of outstanding shares for up to ten years.
  • Closing requires GigCapital5 to have at least $15.0 million of Available Cash and at least $5,000,001 of net tangible assets after redemptions, excluding assets of the surviving corporation.

Material Changes Versus the Prior Comparable Period

The filing does not report period-over-period operating results. The material development is the signing of the proposed business combination, which would change GigCapital5 from a SPAC into the parent of QT Imaging and potentially provide QT Imaging access to public-market capital.

Guidance, Outlook, Risks, Contingencies, and Unusual Items

  • Earnout milestones include FDA clearance for breast cancer screening, at least eight global system placements or $4.4 million of 2023 revenue, $17.1 million of 2024 revenue plus four U.S. placements, and $67.0 million of 2025 revenue or a specified $15.00 VWAP threshold.
  • Additional earnout shares may be released for new FDA clearances, open-angle scanner performance, or positive clinical-trial results.
  • The transaction remains subject to stockholder approvals, SEC effectiveness of a Form S-4 registration statement and proxy statement, regulatory approvals, exchange listing, required consents, financing and cash conditions, and other customary closing conditions.
  • The agreement may be terminated if closing has not occurred by September 8, 2023, if required approvals are not obtained, if specified breaches or material adverse effects occur, or if minimum net tangible asset or other closing conditions fail.
  • Redemptions by GigCapital5 stockholders could reduce Available Cash and jeopardize the minimum cash condition.
  • QT Imaging’s non-in-the-money warrants are expected to be canceled without consideration, while qualifying in-the-money warrants may be assumed and adjusted. Company options are expected to be terminated without conversion or payment.
  • Key risks include failure to complete the transaction, inability to obtain or maintain FDA clearances or exchange listing, competition, demand and sales execution, growth and employee-retention challenges, clinical and product-development risks, transaction costs, litigation, regulatory changes, and COVID-19 effects.

Important Facts for Investors to Verify

  • Whether the Form S-4 and proxy statement are filed and declared effective, and whether GigCapital5 and QT Imaging stockholders approve the transaction.
  • The final exchange ratio, fully diluted capitalization, redemption level, Available Cash, PIPE financing, transaction expenses, and QT Imaging debt at closing.
  • The final number of shares issued to QT Imaging holders, including any dilution from warrants, convertible notes, the equity incentive plan, PIPE securities, and earnout shares.
  • Whether the proposed merger closes by September 8, 2023 and whether the combined company obtains the required NYSE, NYSE American, or Nasdaq listing.
  • QT Imaging’s audited and reviewed PCAOB-compliant financial statements, including historical revenue, losses, cash flow, margins, assets, liabilities, and liquidity, which are not presented clearly in this filing.
  • FDA clearance status, system placements, revenue achievement, clinical results, and the conditions governing each earnout tranche.
  • The detailed terms of the Business Combination Agreement, Stockholder Support Agreement, Sponsor Support Agreement, registration rights, lock-up, and any PIPE subscription agreements.